(Q42815906)

7 November 2017

title

Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305). (English)

1 reference

7 November 2017

1 reference

1 reference

Michinori Ogura

1

1 reference

7 November 2017

Kuniaki Itoh

2

1 reference

7 November 2017

Tomohiro Kinoshita

3

1 reference

7 November 2017

Haruhiko Fukuda

4

1 reference

7 November 2017

Takeaki Takenaka

5

1 reference

7 November 2017

Tomoko Ohtsu

6

1 reference

7 November 2017

Yoshitoyo Kagami

7

1 reference

7 November 2017

Kensei Tobinai

8

1 reference

7 November 2017

Masataka Okamoto

9

1 reference

7 November 2017

Hideki Asaoku

10

1 reference

7 November 2017

Tsuneo Sasaki

11

1 reference

7 November 2017

Chikara Mikuni

12

1 reference

7 November 2017

Masami Hirano

13

1 reference

7 November 2017

Takaaki Chou

14

1 reference

7 November 2017

Kazunori Ohnishi

15

1 reference

7 November 2017

Hitoshi Ohno

16

1 reference

7 November 2017

Kaori Nasu

17

1 reference

7 November 2017

Kenichi Okabe

18

1 reference

7 November 2017

Shuichi Ikeda

19

1 reference

7 November 2017

Shigeo Nakamura

20

1 reference

7 November 2017

Tomomitsu Hotta

21

1 reference

7 November 2017

Masanori Shimoyama

22

1 reference

7 November 2017

publication date

16 November 2010

1 reference

International Journal of Hematology

7 November 2017

published in

1 reference

7 November 2017

volume

92

1 reference

7 November 2017

issue

5

1 reference

7 November 2017

page(s)

713-724

1 reference

Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD)

7 November 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12185-010-0712-8

Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12185-010-0712-8

Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12185-010-0712-8

Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD

21 January 2018

1 reference

12 December 2020

ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors

1 reference

12 December 2020

The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a cas

1 reference

12 December 2020

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease

1 reference

12 December 2020

Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease

1 reference

12 December 2020

Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?

1 reference

12 December 2020

Twenty years of MOPP therapy for Hodgkin's disease

1 reference

12 December 2020

Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.

1 reference

12 December 2020

Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting

1 reference

12 December 2020

ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

1 reference

12 December 2020

Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results

1 reference

12 December 2020

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

1 reference

12 December 2020

Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group

1 reference

12 December 2020

Involved-field radiotherapy for advanced Hodgkin's lymphoma.

1 reference

12 December 2020

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

12 December 2020

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

12 December 2020

Is cyclic chemotherapy better than standard four-drug chemotherapy for Hodgkin's disease? Yes.

1 reference

12 December 2020

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

1 reference

12 December 2020

The world health organization classification of malignant lymphomas in japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists

1 reference

12 December 2020

Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The

1 reference

12 December 2020

Cancer statistics, 2008

1 reference

12 December 2020

Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group

1 reference

12 December 2020

The pathology and nomenclature of Hodgkin's disease.

1 reference

12 December 2020

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

1 reference

12 December 2020

ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results

1 reference

12 December 2020

A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curi

1 reference

12 December 2020

Report of the Committee on Hodgkin's Disease Staging Classification

1 reference

12 December 2020

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study

1 reference

12 December 2020

10.1007/S12185-010-0712-8

Identifiers

DOI

1 reference

7 November 2017

1 reference